PD-1/PD-L1抑制剂治疗晚期卵巢癌的研究进展

Research progress of PD-1/PD-L1 inhibitor in the treatment of advanced ovarian cancer

卵巢癌是妇科恶性肿瘤中常见的类型之一,由于其早期无明显症状,患者就诊时已为晚期。目前晚期卵巢癌的标准治疗主要是以铂类为基础的化疗,但大多数患者会出现复发或耐药后进展等。因此,临床迫切需要新的治疗方法以改善晚期卵巢癌患者的预后。近年来,随着对肿瘤免疫学及分子生物学的不断深入研究,免疫治疗作为一种新兴的治疗肿瘤的方式,为晚期卵巢癌患者提供了新的治疗方向。本文将对晚期卵巢癌免疫治疗的临床研究现状进行综述。

Ovarian cancer is one of the most common types of gynecological malignant tumors.Because there are no obvious symptoms in the early stage,the patients are advanced at the time of treatment.At present,the standard treatment of advanced ovarian cancer is mainly platinum-based chemotherapy,but most patients will have recurrence or post-drug resistance.Therefore,there is an urgent need for new treatments to improve the prognosis of patients with advanced ovarian cancer.In recent years,with the in-depth study of tumor immunology and molecular biology,immunotherapy,as a new way to treat tumors,provides a new treatment direction for patients with advanced ovarian cancer.This article reviews the clinical research status of immunotherapy for advanced ovarian cancer.